Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy.

Published

Journal Article

The translation of fundamental science-based constructs to the preemptive identification and optimal management of individuals with or those at risk for thrombotic disorders of the cardiovascular system has taken a step closer to being realized with the development of molecular technologies that include nucleic acid aptamers and their complimentary oligonucleotide antidotes. Herein, we summarize our experience with factor IX and von Willebrand factor aptamers, and introduce the era of antithrombotic pharmacobiologic therapy.

Full Text

Duke Authors

Cited Authors

  • Becker, RC; Oney, S; Becker, KCD; Rusconi, CP; Sullenger, B

Published Date

  • December 2007

Published In

Volume / Issue

  • 27 / 5

Start / End Page

  • 378 - 382

PubMed ID

  • 18060250

Pubmed Central ID

  • 18060250

International Standard Serial Number (ISSN)

  • 0720-9355

Language

  • eng

Conference Location

  • Germany